Thermo Fisher Scientific Inc.
NYSETMO short interest surges 29% in one week to 1.59% of float, driven by activist shorting ahead of UBS upgrade and elevated analyst price targets.
A new long-form analysis for TMO this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumThree distinct signals have converged on TMO this week. An analyst upgrade, a short interest jump, and elevated put-buying are all pointing in different directions at once. UBS analyst Doug Schenkel upgraded TMO to Buy…
Snapshot as of 20 Sept 2026
Thermo Fisher Scientific heads into the final days of August with two signals pulling in opposite directions: a sharp options-driven defensiveness spike, and a CEO who sold $7 million of stock into a 6.6% weekly…
TMO heads into its Q2 earnings release today with the stock up 13% over the past month but surrounded by a peer group that is cracking under pressure. The peer moves are the sharpest near-term signal. DHR fell 11% on…
TMO reports Q2 results on July 22 with the Street broadly supportive but increasingly cautious on valuation, even as the stock has clawed back ground from a difficult spring. The analyst picture tells the clearest…
Thermo Fisher Scientific heads into its July 22 Q1 results with the stock recovering strongly but the analyst community still cutting numbers — a divergence worth watching closely. The price action this week has been…
Thermo Fisher Scientific notched a strong 7.6% weekly gain to close at $482.08, yet a 2.4% single-day pullback on Tuesday — and a fresh downgrade from HSBC — underline how much tension remains between the stock's…
Thermo Fisher Scientific has just reported Q1 2026 results, and the market's positioning has shifted meaningfully from the defensive crouch seen going in. The clearest signal is in options. Heading into the print, the…
Thermo Fisher Scientific reports tomorrow. Options traders are already positioned. The put-call ratio hit 1.10 on May 18 — down sharply from a 20-day mean of 1.27. That's a z-score of -3.16, a three-standard-deviation…
Thermo Fisher Scientific reports Q1 2026 results on May 20 carrying the weight of a brutal month — down 17% — and a sell-side that has been quietly but consistently trimming its price targets. The analyst story here is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TMO — free to start on ORTEX.
Sign up for free →Open TMO on ORTEX